Remove Antibody Remove Drug Delivery Remove Gene Therapy
article thumbnail

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Pharmaceutical Technology

The next wave came from early research into liposomes and lipid nanoparticles, both of which are used for drug delivery. Liposomes have the same function as lipid nanoparticles in drug delivery but have a simpler formulation. Lipid nanoparticle drug delivery was in the spotlight during the Covid-19 pandemic.

article thumbnail

The 3rd Annual Blood-Brain Barrier Summit Returns in August 2021

pharmaphorum

To achieve this, the agenda will allow delegates to: Explore the translation of BBB-penetrating antibodies to non-human primates , and new possibilities for in vivo brain imaging of antibody neuropharamacokinetics. 3-day Conference | June 28-30, 2021.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

One of the biggest challenges with developing therapies to treat CNS disorders is the delivery of systemically administered investigational products (IPs) to the brain, which is limited by the blood-brain barrier. Some methods of direct CNS administration include intrathecal, intraparenchymal and intracerebroventricular (ICV) delivery.

Trials 83
article thumbnail

FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD)

The Pharma Data

About Roche in Ophthalmology Roche is focused on saving people’s eyesight from the leading causes of vision loss through pioneering therapies. Faricimab is the first investigational bispecific antibody designed for the eye.

article thumbnail

FDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)

The Pharma Data

If approved, this would be the third indication for Vabysmo, the first bispecific antibody available for the treatment of retinal conditions that can cause blindness.” 7 About Vabysmo® (faricimab) Vabysmo is the first bispecific antibody approved for the eye. Roche’s Chief Medical Officer and Head of Global Product Development. “If

article thumbnail

Roche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023

The Pharma Data

4-7 Additionally, phase I data for an investigational anti-interleukin-6 (IL-6) treatment in uveitic macular edema (UME), to be presented for the first time, suggest the monoclonal antibody may improve visual acuity in patients with UME. 1 4 About Vabysmo ® ( faricimab ) Vabysmo is the first bispecific antibody approved for the eye.

article thumbnail

Biopharmaceutical Excipient Manufacturing – Current Scenario and Future Trends

Roots Analysis

In the last decade alone, the annual number of approvals of biopharmaceuticals (including monoclonal antibodies, recombinant proteins, vaccines and gene therapies), by the US FDA, have steadily risen. Over the years, the rising popularity of biologics has led to a paradigm shift in the healthcare industry. Web: [link].